| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Everolimus |
| Brand | Votubia® |
| Indication | For the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC. |
| Assessment Process | |
| Rapid review commissioned | 19/04/2017 |
| Rapid review completed | 26/04/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.